|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variable | Category | N=37 | Response to anti-TNF (%) | Single predictor modela | Multiple predictor modelb |
| OR (95% CI) | P | OR (95% CI) | P |
| Age |  |  |  |  |  | 1.08 (0.80-1.44) | 0.630 |
| Sex | Male | 27 | 14 (51.9) |  |  | 4.20 (0.42-42.52) | 0.224 |
|  | Female | 10 | 3 (30.0) |  |  |  |  |
| Age at diagnosis |  |  |  | 1.16 (0.82-1.65) | 0.403 |  |  |
| IBD subtype | UC/IC | 12 | 6 (50.0) | 1.40 (0.34-5.83) | 0.644 |  |  |
|  | CD | 25 | 11 (44.0) | 1 |  |  |  |
| Biologics | >1 | 14 | 5 (35.7) | 0.48 (0.12-2.02) | 0.319 |  |  |
|  | 1 | 23 | 12 (52.2) | 1 |  |  |  |
| Prior anti-TNF  | Yes | 10 | 5 (50.0) | 1.14 (0.25-5.13) | 0.864 |  |  |
|  | None | 27 | 12 (44.4) | 1 |  |  |  |
| Anti-TNF agent | Infliximab | 25 | 10 (40.0) | 0.58 (0.13-2.50) | 0.465 |  |  |
|  | Not Infliximab | 12 | 7 (58.3) | 1 |  |  |  |
|  | Adalimumab | 8 | 6 (75.0) | 4.52 (0.74-27.80) | **0.103** |  |  |
|  | Not Adalimumab | 29 | 11 (37.9) | 1 |  |  |  |
|  | Certolizumab | 4d | 1 (25.0) | 0.25 (0.02-2.90) | 0.270 |  |  |
|  | Not Certolizumab | 33 | 16 (48.5) | 1 |  |  |  |
| Disease activityc | Active disease | 34 | 14 (41.2) | N.A. |  |  |  |
|  | Not active (remission) | 3 | 3 (100.0) | N.A. |  |  |  |
| EIM diagnosise | Prior to IBD | 9 | 7 (77.8) | 7.99 (1.16-54.87) | **0.034** | 9.70 (1.04-90.04) | **0.046** |
|  | Not prior to IBD | 27 | 10 37.0) | 1 |  |  |  |
|  | After IBD | 24 | 10 (41.7) | 0.34 (0.07-1.69) | **0.189** | 1 |  |
|  | Not after IBD | 12 | 7 (58.3) | 1 |  |  |  |
| IBD to EIM |  |  |  | 0.99 (0.97-1.01) | 0.365 |  |  |
| Number of EIM | >1 | 20 | 9 (45.0) | 0.89 (0.23-3.31) | 0.847 |  |  |
|  | 1 | 17 | 8 (47.1) | 1 |  |  |  |
| EIM subtype | Peripheral arthritis | 13 | 8 (61.5) | 3.63 (0.78-16.93) | **0.100** | 6.83 (0.46-101.50) | 0.163 |
|  | Not peripheral arthritis | 24 | 9 (37.5) | 1 |  |  |  |
|  | Uveitis | 3 | 2 (66.7) | 1.99 (0.15-26.32) | 0.602 |  |  |
|  | Not uveitis | 34 | 15 (44.1) | 1 |  |  |  |
|  | PG | 2 | 1 (50.0) | 0.95 (0.05-17.23) | 0.970 |  |  |
|  | Not PG | 35 | 16 (45.7) | 1 |  |  |  |
|  | EN | 3 | 1 (33.3) | 0.84 (0.05-12.97) | 0.902 |  |  |
|  | Not EN | 34 | 16 (47.1) | 1 |  |  |  |
|  | Stomatitis | 10 | 3 (30.0) | 0.23 (0.04-1.25) | **0.089** | 1 |  |
|  | Not stomatitis | 27 | 14 (51.9) | 1 |  |  |  |
|  | AS | 4 | 2 (50.0) | 1.55 (0.17-14.37) | 0.700 |  |  |
|  | Not AS | 33 | 15 (45.5) | 1 |  |  |  |
|  | PSCc | 0 | 0 (N.A.) | N.A. |  |  |  |
|  | Not PSC | 37 | 17 (45.9) | N.A. |  |  |  |
|  | Psoriasisc | 2 | 0 (0.0) | N.A. |  |  |  |
|  | Not psoriasis | 35 | 17 (48.6) | N.A. |  |  |  |

SUPPLEMENTARY TABLE 2: Multivariate analysis regarding positive anti-TNF outcome.

For 37 of all treated EIM, response to anti-TNF has been reported. AS, axial arthropathy; CI, confidence inerval; EIM, extraintestinal manifestation; EN, erythema nodosum; OR, odds ratio; PG, pyoderma gangrenosum.

aPredictors one-by-one, adjusted for age and sex. OR for age and sex are not shown.

bAll predictors with P<0.25 in model 1, adjusted for each other, age and sex.

cn too low for analysis

dAlthough only 3 courses of CZP treatment have been reported, 4 EIM were treated with CZP (2 within the same CZP treatment course)

eDate from 1 EIM missing